Get started
Author

Natalia Tovar

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study
2021 · Andrew M. Brunner, Jordi Esteve, et al. · Blood · 100
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
2023 · Aina Oliver-Caldés, Verónica González-Calle, et al. · The Lancet Oncology · 98
PDF
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
2024 · Nico Gagelmann, Danai Dima, et al. · Journal of Clinical Oncology · 93
PDF
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
2019 · Uma Borate, Jordi Esteve, et al. · Blood · 85
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
2020 · Andrew M. Brunner, Jordi Esteve, et al. · Blood · 69
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
2018 · Carlos Fernández de Larrea, Ignacio Isola, et al. · Leukemia · 67
Impact of MiRSNPs on Survival and Progression in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
2012 · Carlos Fernández de Larrea, Alfons Navarro, et al. · Clinical Cancer Research · 64
Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution
2013 · N. Tovar, C. F. de Larrea, et al. · Haematologica · 55
PDF
Phase Ib study of sabatolimab ( MBG453 ), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
2023 · Andrew M. Brunner, Jordi Esteve, et al. · American Journal of Hematology · 54
PDF
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents
2010 · C. Fernandez de Larrea, N. Tovar, et al. · Haematologica · 53
PDF
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
2017 · Tania Díaz, Vanina Rodríguez, et al. · Haematologica · 51
PDF
Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors
2022 · Alessandro Gozzetti, Andrea Guarnieri, et al. · American Journal of Hematology · 47
PDF
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
2021 · Aina Oliver-Caldes, Raquel Jiménez, et al. · Journal for ImmunoTherapy of Cancer · 47
PDF
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
2025 · Maximilian Merz, Anca‐Maria Albici, et al. · HemaSphere · 46
PDF
A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma
2015 · Alfons Navarro, Tania Díaz, et al. · Oncotarget · 46
PDF
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
2022 · Mark A. Dawson, Gautam Borthakur, et al. · Clinical Cancer Research · 39
Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution
2022 · Raquel Jiménez-Segura, Laura Rosiñol, et al. · Blood Cancer Journal · 39
PDF
Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
2013 · C Fernández de Larrea, R Jiménez, et al. · Bone Marrow Transplantation · 37
Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light‐chain deposition disease
2012 · Natalia Tovar, Ma Teresa Cibeira, et al. · European Journal Of Haematology · 36
Complement as the enabler of carfilzomib‐induced thrombotic microangiopathy
2020 · Miquel Blasco, Alexandra Martínez‐Roca, et al. · British Journal of Haematology · 29
PDF
Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome
2018 · Natalia Tovar, Luis Gerardo Rodríguez-Lobato, et al. · Amyloid · 28
Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide
2011 · María Teresa Cibeira, Carlos Fernández de Larrea, et al. · Leukemia Research · 28
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
2024 · Christian Recher, Jenny O'Nions, et al. · Blood · 27
PDF
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia
2022 · David F. Moreno, Mónica López‐Guerra, et al. · British Journal of Haematology · 27
PDF
Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous Stem Cell Transplantation
2012 · Natalia Tovar, Carlos Fernández de Larrea, et al. · Transplantation and Cellular Therapy · 27
PDF
Works count: 255
Citation count: 1,757
H-index: 25
I10-index: 42
Year
Topic
Type